(P071) Socioeconomic Disparities in Baseline Magnetic Resonance Imaging (MRI) Utilization and Imaging Characteristics for Prostate Cancer (PCa) Patients Undergoing Radiotherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In this urban, academic center cohort, PCa patients of lower SES were significantly less likely to undergo staging MRI, particularly in the low-risk group. No differences were found in dominant IPL presence, area, ECE, or SVI, except in the low-risk group. Further investigation is required to better understand trends in pretreatment MRI utilization and dominant IPL characteristics differing by SES.

Ayobami Ajayi, BA, Atu Agawu, BS, Neha Vapiwala, MD, Stefan Both, PhD, Zelig Tochner, MD, Curtiland Deville, MD; Department of Radiation Oncology, Perelman School of Medicine

PURPOSE: To determine whether socioeconomic disparities exist in magnetic resonance imaging (MRI) utilization and imaging characteristics for prostate cancer (PCa) patients undergoing radiotherapy.

METHODS: An institutional database identified 598 nonmetastatic PCa patients treated with proton and/or intensity-modulated radiotherapy from 2005–2013 with pretreatment pelvic MRI (T2-weighted, diffusion-weighted, and/or dynamic contrast-enhanced sequences; 91% with endorectal coil). Dominant intraprostatic lesion (IPL) presence, size, extracapsular extension (ECE), and seminal vesicle invasion (SVI) were reviewed. Patients of higher socioeconomic status (SES) vs low SES (defined as geocoded census tract > 20% below the poverty level) overall and stratified by risk group were compared using Fisher’s exact test for categorical variables and Student’s t-test for continuous variables (P < .05 significant).

RESULTS: In this cohort, 437 were classified as higher-SES (73%) and 161 were classified as low-SES (27%). Mean age (67 ± 8 yr), Gleason score, and clinical stage did not differ significantly for higher-SES vs low-SES patients. Low-SES patients were more likely to be black (71%) than higher-SES patients (16%) (P < .001). Low-SES patients also had significantly higher prostate-specific antigen (PSA) levels (higher-SES: 9.5 ± 21 ng/mL, low-SES: 15.6 ± 22 ng/mL; P < .001) and were more likely to be high-risk (higher-SES: 22% vs low-SES: 34%; P = .006). Higher-SES patients had a greater proportion of low-risk patients (38%) than did low-SES subjects (25%; P = .005). Overall, 457 (76%) patients underwent baseline MRI. Low-SES patients (69%) were less likely than higher-SES patients (79%; P = .01) to undergo MRI. This disparity was greatest for low-risk patients (higher-SES: 84%, low-SES: 56%; P < .001) and not significant for intermediate-risk (77% vs 71%; P = .389) or high-risk patients (77% vs 81%; P = .675). There were no significant differences between SES groups in dominant IPL presence, diameter, area, ECE, or SVI-overall or within intermediate- and high-risk groups. Low-risk, low-SES patients demonstrated larger dominant IPL area (133.5 ± 141 mm2 vs 66.7 ± 58 mm2; P = .017), with no differences in dominant IPL diameter or presence, additional IPLs, ECE, or SVI.

CONCLUSIONS: In this urban, academic center cohort, PCa patients of lower SES were significantly less likely to undergo staging MRI, particularly in the low-risk group. No differences were found in dominant IPL presence, area, ECE, or SVI, except in the low-risk group. Further investigation is required to better understand trends in pretreatment MRI utilization and dominant IPL characteristics differing by SES.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content